Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.44% | 9.21% | 4.55% | 23.42% | 10.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.44% | 9.21% | 4.55% | 23.42% | 10.86% |
| Cost of Revenue | 16.13% | 10.02% | 9.20% | 24.87% | 19.29% |
| Gross Profit | 51.51% | 8.72% | 1.56% | 22.45% | 4.69% |
| SG&A Expenses | 16.88% | -8.57% | 4.63% | 3.62% | -7.62% |
| Depreciation & Amortization | -- | -- | -- | -91.48% | -37.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.25% | -4.01% | 2.71% | 9.44% | 1.39% |
| Operating Income | 12,006.25% | 171.27% | 29.48% | 829.58% | 97.95% |
| Income Before Tax | 360.69% | 436.34% | 32.72% | 158.49% | 58.58% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 136.36% |
| Earnings from Continuing Operations | 357.95% | 440.76% | 33.02% | 157.92% | 57.89% |
| Earnings from Discontinued Operations | 4.65% | 66.36% | -31.65% | 147.77% | 99.34% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 308.47% | 1,078.29% | 33.33% | 156.91% | 95.68% |
| EBIT | 12,006.25% | 171.27% | 29.48% | 829.58% | 97.95% |
| EBITDA | 788.84% | 95.29% | -10.18% | 180.65% | 254.48% |
| EPS Basic | 304.92% | 1,060.59% | 31.41% | 156.09% | 95.75% |
| Normalized Basic EPS | 356.33% | 428.72% | 30.79% | 162.04% | 59.33% |
| EPS Diluted | 304.99% | 1,108.21% | 30.43% | 154.07% | 95.76% |
| Normalized Diluted EPS | 354.62% | 425.78% | 30.32% | 161.93% | 59.33% |
| Average Basic Shares Outstanding | 1.71% | 1.51% | 1.46% | 1.43% | 1.82% |
| Average Diluted Shares Outstanding | 2.41% | 1.97% | 1.76% | 1.62% | 1.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
